Page last updated: 2024-11-04

rofecoxib and Cough

rofecoxib has been researched along with Cough in 1 studies

Cough: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.

Research Excerpts

ExcerptRelevanceReference
"The aim of this study was to examine the influence of regulatory measures and other external factors on the rate of ADR reporting in Italy, focusing on four situations occurring in the last 10 years: ACE inhibitor-induced cough; HMG-CoA reductase inhibitors ('statins') and rhabdomyolysis; nimesulide and hepatic toxicity; and cyclo-oxygenase (COX)-2 selective inhibitors ('coxibs') and increase in cardiovascular risk."3.74Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy. ( Conforti, A; Leone, R; Montanaro, N; Moretti, U; Motola, D; Vaccheri, A; Vargiu, A; Velo, G, 2008)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Motola, D1
Vargiu, A1
Leone, R1
Conforti, A1
Moretti, U1
Vaccheri, A1
Velo, G1
Montanaro, N1

Other Studies

1 other study available for rofecoxib and Cough

ArticleYear
Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.
    Drug safety, 2008, Volume: 31, Issue:7

    Topics: Adverse Drug Reaction Reporting Systems; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Di

2008